Public Release: 


Research Australia

Ventracor Limited (ASX: VCR) moved a step closer to completing enrolment in its CE Mark Trial announcing the successful implant of its left ventricular assist device (LVAD), the VentrAssist, at Norway's Rikshopitalet University Hospital.

Ventracor Limited Chief Executive Officer Colin Sutton PhD said: "Clinical knowledge and experience in surgical procedures and patient management is growing rapidly.

"Recent implants in Norway, Perth, Sydney, Auckland and Brisbane bring enrolments in the CE Mark Trial closer to completion.

"We expect there will be additional implants in the coming weeks and are on track to complete recruitment in the CE Mark Trial before the end of the first quarter 2006."

Dr Sutton added Ventracor had developed training programs and added field support which would allow the company to carefully expand the number of European hospitals implanting the VentrAssist LVAD.

Ventracor's CE Mark Trial is aimed at obtaining approval to sell the VentrAssistTM in the major market of Europe.

Dr Sutton added Ventracor continued to focus on achieving key milestones.


About Ventracor
Ventracor is a global medical device company that has developed a blood pump, the VentrAssistTM left ventricular assist system (LVAS) for patients in cardiac failure. The company hopes to bring the VentrAssistTM to the global market in record time, and expects to obtain a significant share of the huge potential market.

For further information, please contact:
Andrew Geddes
Manager, Investor Relations
Ventracor Limited

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.